Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | PTGES | O14684 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ITGAL | P20701 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681764 | 1.00 | PLA2G4A (0.78) | PLA2G4AMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL3680268 | 0.87 | TDP1 (0.67) | PLA2G4AMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL3680272 | 0.87 | TDP1 (0.67) | PLA2G4AMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL27490600 | 0.87 | PLA2G4A (0.76) | PLA2G4AMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL25233892 | 0.84 | MAPT (0.64) | PLA2G4AMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL25195164 | 0.84 | MAPT (0.64) | PLA2G4AMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL5661855 | 0.82 | MAPT (0.72) | PLA2G4AMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL30951735 | 0.82 | PLA2G4A (0.65) | PLA2G4AMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL5830443 | 0.82 | ITGAL (0.74) | PLA2G4AMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL2959825 | 0.78 | MAPT (0.71) | MAPTMEN1KMT2ANPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1660427-A4 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | PLA2G4A 460/4885MAPT 4869/4885MEN1 4864/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | PLA2G4A 460/4885MAPT 4869/4885MEN1 4864/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | PLA2G4A 460/4885MAPT 4869/4885MEN1 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.